A cost‐effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome

Abstract

Cell free DNA screening is a cost-effective replacement for maternal serum screening when the lifetime costs of Down syndrome live births are considered. The adoption of cfDNA screening would save approximately $277 955 for each additional case detected over integrated screening.